NCT07223138Phase 3Enrolling by invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Study sponsor: MoonLake Immunotherapeutics AG

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-02-04Estimated
Enrollment · participants1560Estimated
Source updated2026-11-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Enrolling by invitation.

Check registry source